Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Firm”), a clinical-stage biotech firm growing RNA interference (RNAi) therapies for KRAS-driven cancers, at the moment introduced the entry into definitive agreements for the instant train of sure excellent warrants to buy as much as an mixture of 152,106 of the Firm’s strange shares initially issued in January 2025 at a diminished train value of $11.57 per share. The strange shares issuable upon train of the warrants are registered pursuant to an efficient registration assertion on Kind S-1 (File No. 333-282932) and an efficient resale registration assertion on Kind S-1 (No. 333-284873). The gross proceeds to the Firm from the train of the warrants are anticipated to be roughly $1.8 million, previous to deducting placement agent charges and estimated providing bills. The providing is anticipated to shut on or about August 1, 2025, topic to satisfaction of customary closing situations. The Firm intends to make use of the web proceeds from the providing as working capital for basic company functions.
H.C. Wainwright & Co. is performing because the unique placement agent for the providing.
In consideration for the instant train of the warrants for money, the Firm will subject new unregistered warrants to buy as much as 304,212 of the Firm’s strange shares. The brand new warrants may have an train value of $11.32 per share, shall be exercisable upon the efficient date of the rise of the Firm’s approved strange shares following shareholder approval and may have a time period of twenty-four months from the efficient date of the Resale Registration Assertion (as outlined under).
The brand new warrants described above had been supplied in a non-public placement pursuant to an relevant exemption from the registration necessities of the Securities Act of 1933, as amended (the “1933 Act”) and, together with the strange shares issuable upon their train, haven’t been registered below the 1933 Act, and might not be supplied or offered in the US absent registration with the Securities and Alternate Fee (“SEC”) or an relevant exemption from such registration necessities. The Firm has agreed to file a registration assertion with the SEC masking the resale of the strange shares issuable upon train of the brand new warrants (the “Resale Registration Assertion”).
This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase nor shall there be any sale of these securities in any state or jurisdiction through which such provide, solicitation or sale can be illegal previous to the registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About Silexion Therapeutics
Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology firm growing revolutionary RNA interference (RNAi) therapies to deal with stable tumors pushed by KRAS mutations, the most typical oncogenic driver in human cancers. The Firm’s first-generation product, LODER™, has proven promising leads to a Section 2 trial for non-resectable pancreatic most cancers. Silexion can be advancing its next-generation siRNA candidate, SIL-204, designed to focus on a broader vary of KRAS mutations and displaying vital potential in preclinical research. The corporate stays dedicated to pushing the boundaries of therapeutic innovation in oncology, with a give attention to enhancing outcomes for sufferers with difficult-to-treat cancers. For extra data please go to: https://silexion.com
Discover Relating to Ahead-Trying Statements
This press launch accommodates forward-looking statements inside the which means of the federal securities legal guidelines. All statements aside from statements of historic truth contained on this communication, together with statements relating to the completion of the providing, the satisfaction of customary closing situations associated to the providing and the meant use of web proceeds from the providing. These forward-looking statements are typically recognized by terminology comparable to “could”, “ought to”, “might”, “may”, “plan”, “potential”, “mission”, “attempt”, “price range”, “forecast”, “anticipate”, “intend”, “will”, “estimate”, “anticipate”, “imagine”, “predict”, “potential” or “proceed”, or the negatives of these phrases or variations of them or related terminology. For instance, the Firm is utilizing forward-looking statements when it discusses the timing and completion of the providing, the satisfaction of customary closing situations associated to the providing and the meant use of proceeds therefrom. Ahead-looking statements contain a quantity of dangers, uncertainties, and assumptions, and precise outcomes or occasions could differ materially from these projected or implied in these statements. Vital elements that might trigger such variations embody, however are usually not restricted to: (i) whether or not Silexion is ready to efficiently full preclinical research and provoke scientific trials; (ii) Silexion’s technique, future operations, monetary place, projected prices, prospects, and plans; (iii) the impression of the regulatory setting and compliance complexities; (iv) expectations relating to future partnerships or different relationships with third events; (v) Silexion’s future capital necessities and sources and makes use of of money, together with its potential to acquire further capital; and (vi) whether or not Silexion succeeds at sustaining the itemizing of its securities on the Nasdaq Capital Market. Silexion cautions you towards inserting undue reliance on forward-looking statements, which replicate present beliefs and are based mostly on data at present obtainable as of the date a forward-looking assertion is made. Ahead-looking statements set forth herein communicate solely as of the date they’re made. Silexion undertakes no obligation to revise forward-looking statements to replicate future occasions, adjustments in circumstances, or adjustments in beliefs, besides as in any other case required by legislation.
Firm Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx | Capital Market Advisors
North American Equities Desk
silexion@arxadvisory.com
Source link
#Silexion #Therapeutics #Announces #Exercise #Warrants #Million #Gross #Proceeds
